Jun 2026 $4 M Private placement after listing $2 to $10 million 5
Arcadia Biosciences, Inc.: Private sale, Jun 2026 × Investors in this round 5 investors had bought by the notice of Jun 26, 2026: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Arcadia Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $4 M of $11 M offered; $7 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $395,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Thomas J. Schaefer · Executive Officer, Director Amy J. Yoder · Director Gregory D Waller · Director Kevin J. Comcowich · Director Lilian Shackelford Murray · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co, LLC (CRD 375) · New York, New York Sold in NY Remarks in the notice On fees: “In addition to cash fee, the company paid certain expenses of $75,000 and issued placement agent preferred investment options to purchase up to 271,845 shares of common stock at exercise price $1.2875 per share.”On the amounts: “Includes gross proceeds received from issuance of pre-funded warrants & preferred investment options. Offering also reflects the aggregate exercise price of pre-funded warrants, preferred investment options and placement agent investment options issued.”Signed by Thomas J. Schaefer, Ceo. Source: SEC Form D, newest notice filed Jun 26, 2026. Read the notice at the SEC .
equity, options SEC Jan 2026 $2 M Private placement after listing $2 to $10 million 3
Arcadia Biosciences, Inc.: Private sale, Jan 2026 × Investors in this round 3 investors had bought by the notice of Jan 27, 2026: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Arcadia Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $6 M offered; $4 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $145,749
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Thomas J. Schaefer · Executive Officer, Director Albert D. Bolles · Director Amy D. Yoder · Director Deborah D. Carosella · Director Gregory D. Waller · Director Kevin J. Comcowich · Director Lilian Shackelford Murray · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co, LLC (CRD 375) · New York, New York Sold in NY Remarks in the notice On fees: “In addition to the cash fee above, the company paid certain expenses of $75,000 and issued placement agent preferred investment options to purchase up to 56,602 shares of common stock at an exercise price of $3.2188 per share”On the amounts: “Includes gross proceeds received by company from issuance of shares upon exercise of warrants. Total offering also reflects the aggregate exercise price of inducement preferred investment options issued and placement agent investment options issued.”Signed by Thomas J. Schaefer, Ceo. Source: SEC Form D, newest notice filed Jan 27, 2026. Read the notice at the SEC .
equity, options SEC Jan 2021 $25 M Private placement after listing $10 to $50 million 26
Arcadia Biosciences, Inc.: Private sale, Jan 2021 × Investors in this round 26 investors had bought by the notice of Feb 16, 2021: 26 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Arcadia Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $25 M of $25 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, other: Common stock and warrants to purchase common stock Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,750,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Matthew T Plavan · Executive Officer, Director Pam T Haley · Executive Officer Albert D Bolles · Director Amy D Yoder · Director Gregory D Waller · Director Kevin T Comcowich · Director Lilian Shackelford Murray · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · broker-dealer H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in CT, NJ, NY Signed by Pam Haley, Cfo. Source: SEC Form D, newest notice filed Feb 16, 2021. Read the notice at the SEC .
equity, options SEC Mar 2018 $10 M Private placement after listing $10 to $50 million 2
Arcadia Biosciences, Inc.: Private sale, Mar 2018 × Investors in this round 2 investors had bought by the notice of Apr 11, 2018: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Arcadia Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, other: Common stock and Warrants to Purchase Common Stock Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees $700,000
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Matthew T Plavan · Executive Officer Rajendra T Ketkar · Executive Officer, Director Amy D Yoder · Director Eric T Ray · Director Gregory D Waller · Director Kevin T Comcowich · Director Uday T Garg · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co. LLC · New Hork, New York Sold in NY Signed by Matthew T Plavan, Cfo. Source: SEC Form D, newest notice filed Apr 11, 2018. Read the notice at the SEC .
equity, options SEC Mar 2014 $19 M No. 3 $10 to $50 million 8
Arcadia Biosciences, Inc.: Raise no. 3, Mar 2014 × Investors in this round 8 investors had bought by the notice of Apr 25, 2014: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Arcadia Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $19 M of $36 M offered; $17 M still to sell
Smallest investment taken $10,000
What was sold equity, options or other rights to buy securities, other: Series D Preferred Stock and Warrants to Purchase Common Stock Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $2,000,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Arizona People named in the notice Eric J. Rey · Executive Officer, Director Darby J. Shupp · Director James J. Reis · Director Mark J. Wong · Director Rachel J. Sheinbein · Director Steven J. Brandwein · Director Uday J. Garg · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Piper Jaffray & Co. (CRD 665) · Minneapolis, Minnesota Sold in AZ Remarks in the notice On fees: “Up to $2,000,000 will be paid to Piper Jaffray & Co. as sales compensation, assuming full subscription of Total Offering Amount”Signed by Eric J. Rey, President and CEO. Source: SEC Form D, newest notice filed Apr 25, 2014. Read the notice at the SEC .
equity, options SEC Oct 2009 $2 M No. 2 $2 to $10 million 6
Arcadia Biosciences, Inc.: Raise no. 2, Oct 2009 × Investors in this round 6 investors had bought by the notice of Nov 25, 2009: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Arcadia Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $12 M offered; $10 M still to sell
Smallest investment taken $1
What was sold equity
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $110,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Arizona People named in the notice Eric Rey · Executive Officer Steven Brandwein · Executive Officer David Collier · Director James Reis · Director Jonathan Thatcher · Director Mark Wong · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Steven F Brandwein, VP Finance and Administration. Source: SEC Form D, newest notice filed Nov 25, 2009. Read the notice at the SEC .
equity SEC Jul 2008 $15 M No. 1 $10 to $50 million 9
Arcadia Biosciences, Inc.: Raise no. 1, Jul 2008 × Investors in this round 9 investors had bought by the notice of Aug 4, 2009: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Arcadia Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $15 M of $15 M offered
Smallest investment taken $1
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $611,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Arizona People named in the notice Eric Rey · Executive Officer Steve Brandwein · Executive Officer David Collier · Director James Reis · Director Jonathan Thatcher · Director Mark Wong · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Executives' payroll and benefits and board member remuneration”Signed by Steve Brandwein, VP Finance & Administration. Source: SEC Form D, newest notice filed Aug 4, 2009. Read the notice at the SEC .
equity SEC